The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34132782/
Activating mutations in MYD88 promote malignant cell growth and survival through HCK mediated BTK activation. Ibrutinib binds to BTKCys481 and is active in B-cell malignancies driven by mutated MYD88. Mutations...
56 year old Female with newly diagnosed Richter’s transformation. Stage II-X of neck. Path shows DLBCL arising from CLL. No PMH of significance.
What would be your next steps for this patient?
Molecular classification of aggressive lymphomas-past, present, future - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34105819/
Aggressive large B-cell lymphomas (LBCLs) represent a frequent but clinically and molecularly heterogeneous group of tumors. Technological advances over the last decades prompted the development of different classification schemas to...
Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34109978/
Background: Diffuse large B-cell lymphoma used to be defined as germinal center B-like and non-germinal center B-like subtypes, associated with different prognoses, but the conventional classification does not meet the...
EHA Preview: Advances, Outcomes in CAR T-Cell Therapies and Management Challenges
With 5 chimeric antigen receptor (CAR) T-cell therapies approved by the FDA, and 299 agents in the pipeline, it's no surprise that the virtual meeting of the European Hematology Association...